Distinguished in Dementia

Ralf Reilmann

Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
Distinguished in Dementia
Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
OverviewLocationsClinical Research

Overview

Ralf Reilmann practices in Tuebingen, Germany. Mr. Reilmann is rated as a Distinguished expert by MediFind in the treatment of Dementia. His top areas of expertise are Huntington Disease, Movement Disorders, Chorea, and Dementia.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 93 articles and participated in 5 clinical trials in the study of Dementia.

Gender
Male

Locations

Hoppe Seyler Str. 3, Tuebingen, BW 72076, Germany
Other Locations
Technology Park, Muenster, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
Enrollment Status: Terminated
Publish Date: April 25, 2022
Intervention Type: Drug
Study Drug: WVE-120102
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease
Enrollment Status: Terminated
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drug: WVE-120101
Study Phase: Phase 1/Phase 2
A Longitudinal Cohort Study With Nested Randomised Pragmatic Controlled Trial to Evaluate Physical Activity and Exercise Related Outcomes in People With Huntington's Disease
A Longitudinal Cohort Study With Nested Randomised Pragmatic Controlled Trial to Evaluate Physical Activity and Exercise Related Outcomes in People With Huntington's Disease
Enrollment Status: Unknown
Publish Date: November 05, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
View 4 Less Clinical Trials

120 Total Publications

Isometric force matching in the TRACK-HD study - a novel quantitative assessment for clinical applications?
Isometric force matching in the TRACK-HD study - a novel quantitative assessment for clinical applications?
Journal: Journal of Huntington's disease
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Reilmann's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile